GoodRx expanded access to oral semaglutide for type 2 diabetes patients through its prescription savings platform, offering self-pay pricing with three monthly dosage tiers. The company said prices start as low as $149 per month for eligible self-pay patients via its nationwide pharmacy network. Novo Nordisk is manufacturing the oral formulation, and the companies framed the move as a transparent pricing alternative to the injectable Ozempic option. GoodRx also emphasized it serves nearly 25 million consumers and more than one million healthcare professionals. The update matters for biotech and pharma distributors because it provides a new direct-to-consumer access channel that could accelerate utilization of semaglutide formulations outside traditional payer workflows.